Skin tags, medically termed acrochordons, are common benign epithelial overgrowths that arise from the skin surface and are typically attached by a narrow stalk. They most often occur in intertriginous or friction-prone areas, including the neck, axillae (armpits), inframammary folds, eyelids, and groin. Although usually asymptomatic, they may become irritated, bleed with trauma, or worsen cosmetically—prompting clinical evaluation.
Epidemiology and risk associations
Acrochordons increase in frequency with age and are observed across all skin types. Several clinical observations link skin tags with metabolic dysregulation, particularly insulin resistance and hyperinsulinemia. Hyperinsulinemia can promote cellular proliferation through mitogenic signaling, including activation of insulin/IGF (insulin-like growth factor) pathways. In turn, these pathways may increase epidermal growth and alter local tissue homeostasis, predisposing some individuals to acrochordon development. This association does not mean skin tags are a diagnostic marker of diabetes or insulin resistance in every person; rather, they can function as an external clue suggesting metabolic risk when they occur in greater number, at younger ages, or alongside other features of insulin resistance.
Pathophysiology: why “benign” lesions can track with metabolic risk
Histologically, acrochordons typically show fibroepithelial projections with an overlying epidermis and variable collagen and vascular components. Mechanical factors likely contribute to localized susceptibility. Areas with friction and skin maceration may create chronic microtrauma and local inflammatory signaling, which can favor exophytic growth. Simultaneously, insulin/IGF signaling may enhance growth factor activity, shifting the balance toward proliferation and preventing normal regression of minor epithelial growths. The convergence of mechanical stress, local inflammation, and systemic metabolic signaling provides a plausible model for why acrochordons are more common in individuals with obesity and metabolic syndrome.
Clinical presentation and differential diagnosis
Skin tags appear as soft, pedunculated, skin-colored to hyperpigmented papules or small plaques. Their size ranges from a few millimeters to larger, lobulated lesions. Because skin lesions can be confused with malignant or premalignant growths, clinicians should consider differentials when lesions are atypical. Differential diagnoses include seborrheic keratoses, papillomas, genital warts (HPV-related), and, rarely, melanoma or squamous neoplasms when a lesion is ulcerated, rapidly enlarging, irregularly pigmented, or markedly painful.
When to evaluate metabolic health
If a patient develops multiple skin tags—especially in the neck and axillae at a relatively young age—or if there are concurrent signs of insulin resistance (e.g., central weight gain, acanthosis nigricans, dyslipidemia, hypertension, or family history of type 2 diabetes), clinicians often consider screening for metabolic dysfunction. Practical evaluation may include fasting plasma glucose, HbA1c, and lipid profile. The goal is not to treat skin tags as a standalone disease, but to recognize possible systemic risk.
Management: lesion removal vs risk reduction
Treatment of acrochordons is elective and symptom-driven. For cosmetic concerns or recurrent irritation, office-based options include cryotherapy (liquid nitrogen), electrosurgery/cautery, snip excision with local anesthesia, or ligation (especially for small pedunculated lesions). Recurrence is uncommon when lesions are completely removed, though new lesions can develop over time, particularly if underlying metabolic risk persists.
Evidence-based lifestyle and metabolic interventions
Because the insulin resistance link is associated with hyperinsulinemia and broader metabolic syndrome risk, risk reduction strategies can be clinically relevant. Weight management through caloric control, increased physical activity, and improved diet quality can reduce insulin resistance. In appropriate patients, clinicians may also consider pharmacologic management for diabetes or prediabetes under standard care pathways. Importantly, removing existing skin tags does not “cure” insulin resistance; rather, it addresses the visible lesion while metabolic care addresses the underlying risk.
Safety and appropriate follow-up
Individuals should avoid home removal methods such as tying off lesions or cutting them, which increases risk of bleeding, infection, and scarring. Medical assessment is recommended for lesions that change in color or shape, become painful, bleed spontaneously, or develop an irregular surface texture. A clinician can confirm benign features (and, if needed, biopsy atypical lesions) to ensure safety.
Bottom line
Skin tags are benign, common lesions shaped by frictional microtrauma and benign epithelial growth, but their distribution and number can correlate with insulin resistance and elevated blood sugar risk. In patients with multiple acrochordons—particularly when accompanied by other metabolic indicators—screening for glucose dysregulation and cardiovascular risk factors is a prudent, evidence-aligned approach.
Source: @Shweta150990
Shweta: 🔟 Skin Tags Small skin tags around the neck, armpits, or chest are sometimes associated with insulin resistance and elevated blood sugar levels.. #breaking
— @Shweta150990 May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
